^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy
Published date:
05/02/2023
Excerpt:
In this cohort study of patients with advanced solid tumors treated with ICIs in diverse clinics, TMB-H cancers were significantly associated with improved clinical outcomes compared with TMB-L cancers....Our results were generally consistent with our pancancer cohort, with the 1-year survival probability of TMB-H patients being higher than that of TMB-L patients with NSCLC, bladder, melanoma, and CRC (Figure 3).
DOI:
10.1001/jamanetworkopen.2023.11181
Source:
Title:
Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy
Published date:
09/08/2022
Excerpt:
NON-SUPPORTIVE EVIDENCE: In this study, we analyzed the potential genomic indicators contributing to ICB therapy response. The results showed that high tumor mutation burden (TMB) failed to predict response in anti-PD1 treated melanoma. SERPINB3 was the most significant response-related gene in melanoma...
DOI:
10.3390/cells11182802
Source:
Title:
Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
Published date:
01/31/2022
Excerpt:
...we sought to evaluate the ability of TMB-H to predict the PFS of ICB-treated patients in high TMB (category I) cancer types...we found that TMB-H was remarkably associated with improved PFS after ICB treatment in melanoma and NSCLC...
DOI:
10.1136/jitc-2021-003087
Source:
Title:
1053P - Tumour mutational burden (TMB) assessment using next generation sequencing (NGS) for the prediction of complete response (CR) to immunotherapy (IO) in metastatic melanoma
Published date:
09/13/2021
Excerpt:
MB correlated strongly with CR (p<0.001) with a median TMB of 13.3 (EP) vs 53.2 (CR)...Overall, TMB measured using the TSO 500 is a strong predictor of CR.
Source:
Title:
TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.
Published date:
05/19/2021
Excerpt:
We systematically evaluated all melanoma patients who started adjuvant PD-1 antibody therapy...Patients with BRAF V600E/K mutation and TMB high had the best outcome….
DOI:
10.1200/JCO.2021.39.15_suppl.9524
Source:
Title:
Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma
Published date:
09/24/2020
Excerpt:
...we collected and analyzed WES data and clinicopathologic information of 318 melanoma patients treated with ICIs from the included studies...Univariate Cox regression analysis revealed that patients with high TMB presented a tendency toward better OS in the cohorts...
DOI:
10.1002/cam4.3481
Source:
Title:
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Published date:
08/12/2019
Excerpt:
Histologies that were TMB-high included melanoma (N = 6), bladder cancer (N = 2), cutaneous squamous cell carcinoma (N =2), glioblastoma (N = 1), breast cancer (N = 1), basal cell carcinoma (N = 1), esophageal carcinoma (N = 1), and prostate cancer (N = 1)...All patients were treated with either PD-1/L1 or CTLA4 checkpoint blockade (some received a combination of these agents)...The median PFS for TMB-high tumors compared to TMB-Low to -Intermediate tumors was 26.8 months vs. 4.3 months. (P = 0.0173, HR 0.42 [95% CI 0.22–0.77])...
DOI:
10.1158/2326-6066.CIR-19-0149
Test:
Source:
Title:
The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis
Excerpt:
Compared with low TMB patients receiving ICIs, high TMB yielded a better ORR (RR = 2.73; 95% CI: 2.31–3.22; P = 0.043) and DCB (RR = 1.93; 95% CI: 1.64–2.28; P = 0.356), and a significantly increased OS (HR =0.24; 95% CI: 0.21–0.28; P < 0.001) and PFS (HR = 0.38; 95% CI: 0.34–0.42; P < 0.001)....We found that after immunotherapy for colorectal cancer, gastric cancer, lung cancer, melanoma and pan-cancer, the OS improvement in the high TMB group was significantly better than non-ICIs.
DOI:
https://doi.org/10.1016/j.tranon.2022.101375
